Using the PfEMP1 Head Structure Binding Motif to Deal a Blow at Severe Malaria by Patarroyo, Manuel E. et al.
Using the PfEMP1 Head Structure Binding Motif to Deal a
Blow at Severe Malaria
Manuel E. Patarroyo1,2*, Martha Patricia Alba1,3, Hernando Curtidor1,3, Magnolia Vanegas1,3,
Hannia Almonacid1, Manuel A. Patarroyo1,3
1 Fundacio´n Instituto de Inmunologı´a de Colombia (FIDIC), Bogota´, Colombia, 2 School of Medicine, Universidad Nacional de Colombia, Bogota´, Colombia, 3 School of
Medicine and Health Sciences, Universidad del Rosario, Bogota´. Colombia
Abstract
Plasmodium falciparum (Pf) malaria causes 200 million cases worldwide, 8 million being severe and complicated leading to
,1 million deaths and ,100,000 abortions annually. Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) has
been implicated in cytoadherence and infected erythrocyte rosette formation, associated with cerebral malaria; chondroitin
sulphate-A attachment and infected erythrocyte sequestration related to pregnancy-associated malaria and other severe
forms of disease. An endothelial cell high activity binding peptide is described in several of this ,300 kDa hypervariable
protein’s domains displaying a conserved motif (GACxPxRRxxLC); it established H-bonds with other binding peptides to
mediate red blood cell group A and chondroitin sulphate attachment. This motif (when properly modified) induced PfEMP1-
specific strain-transcending, fully-protective immunity for the first time in experimental challenge in Aotus monkeys,
opening the way forward for a long sought-after vaccine against severe malaria.
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Introduction
Malaria-infected children’s sera originally recognised PfEMP1
in infected erythrocyte (IE) agglutination tests [1], as a highly
polymorphic very large (,300 kDa molecular weight); protein
encoded by .60 variable, genes (Pf var). PfEMP1 has an
extracellular ectodomain consisting of 2 to 9 highly variable in
amino acid sequence, length and composition domains; constitut-
ed by an N-terminal segment (NTS), a Duffy-binding-like (DBL)
1a domain and a cysteine interdomain region (CIDR) a1 (forming
the head structure) and DBL2X, C2, DBL3X, DBL4e, DBL5e,
DBL6e and DBL7e domains followed by a transmembrane region
(TM), and an intracytoplasmic acidic terminal segment (ATS),
inserted into IE membrane [2–4].
PfEMP1 can be classified into 5 groups (A–E) based on the
nucleotide sequence similarity of the upstream promoter sequence
(UPS) [5], having 6 major DBL domain classes (a, b, c, d, e and
X). Each DBL domain consist of hypervariable and conserved
regions and contains 3 subdomains (S1, S2 and S3) having 10
semi-conserved homology blocks (HB 1–10 consisting of 7 to 21
residues) conserved in all domain classes, most frequently localised
in subdomains S1 (HB4), S2 (HB3, HB5) and S3 (HB2, HB1)
[5,6].
PfEMP1 can also be grouped according to 23 domain cassettes
(DC), the most frequent ones DC1 to 3, spanning the entire
protein while the others include 2–4 domains [6].
The DBLa1 domain, binds blood group A and forms rosettes by
adhering to uninfected erythrocytes (UE) [7] being associated with
cerebral malaria (CM) [8]. DBL3X and DBL6e bind to
chondroitin sulphate proteoglycans (CSPG) whilst DBL2X,
DBL3X, DBL5e and DBL6e bind to chondroitin sulphate-A
(CSA) [9,10], leading to IE sequestration in the placenta, thereby
inducing pregnancy-associated malaria (PAM) and abortions,
mainly in primigravidas.
A robust, highly specific, sensitive functional methodology has
been thoroughly described for tailor-made vaccine development
aimed at PfEMP1 (ipso facto severe malaria), recognising variable
and conserved HABPs (cHABPs) in relevant invasion molecules by
working with ,15 to 20 mer-long peptides [11]. cHABPs are
immunologically silent since they do not induce immune
responses; however, when their critical binding residues have
been properly modified [12–14] they become highly immunogenic
and protection-inducing modified HABPs (mHABPs).
Materials and Methods
Ethics Statement
The present study was approved by the Fundacio´n Instituto de
Inmunologı´a’s animal ethics committee. The capture of Aotus
monkeys (International Union for Conservation of Nature and
Natural Resources (IUCN) status: least concern), the pertinent
maintenance, immunization challenge and research procedures
have been authorized by the official Colombian environmental
authority in the Amazonian region (CORPOAMAZONIA,
resolutions 0066/Sep/2006, 0028/May/2010, 0632/Jun/2010
and 0042/Jan/2011 and previous authorizations beginning in
1982).
The US Committee on the Care and Use of Laboratory
Animals’ guidelines were followed for all animal handling
procedures, in turn complying with Colombian regulations for
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Figure 1. Identification of PfEMP1 HABPs and variability sequence between Plasmodium falciparum strains. (A) Dd2 PfEMP1-based
amino-acid sequence synthetic peptides’ RBC and C32 cell binding activity (black bars represent specific binding activity slope); above 2% (dotted
line) were considered HABPs [11–14]. Blue shows HABPs chosen for immunization and red those containing canonical or homologous
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biomedical research (resolution 8430/1993 and law 84/1989).
Monkeys at the station were numbered, sexed, weighed, given a
physical-clinical exam and kept temporally in individual cages,
prior to all experimental procedures. They were kept in controlled
conditions regarding temperature (25u–30u centigrade) and
relative humidity (83%), similar to those present in their natural
environment. The monkeys’ diet was based on a supply of fruit
typical of the amazon region (i.e. such primates’ natural diet),
vegetables and a nutritional supplement including vitamins,
minerals and proteins. Environmental enrichment included visual
barriers to avoid social conflict, feeding devices, some branches
and vegetation, perches and habitat. Any procedure requiring
animal handling was practiced by trained veterinary personnel
and animals were submitted to sedation and analgesia procedures
to reduce stress when necessary [15]. The monkeys were cared for
by expert veterinarians and biologists and supervised weekly by
CORPOAMAZONIA veterinarians.
All individuals were released back into the Amazon jungle after
the experimental procedures and 30–40 days of quarantine and
clinical evaluation in optimal health conditions, as approved by
CORPOAMAZONIA and in the presence of its officials.
Peptide Synthesis and Radiolabelling
All peptides were synthesised using standard t-Boc solid-phase
peptide synthesis (SPPS) strategy [16]. A tyrosine residue was
added to the C-terminus of peptides lacking it to allow
radiolabelling, as widely described [14].
Polymeric peptides were obtained for immunisation purposes by
adding CG to N- and -C termini, as previously described [14].
Binding Assays with PfEMP1 Peptides
PfEMP1 binding to endothelial cells (C32 cells) and RBC was
performed according to previously described protocols [14].
Peptides having binding activity greater than or equal to 2%
(0.02 ratio) were considered high-activity binding peptides
(HABPs), according to previously-established criteria [11].
Animals and Immunisation
Groups of 4–10 Aotus monkeys proving IFA negative for P.
falciparum blood stage, kept in our monkey colony in the Amazon
jungle (Leticia, Colombia) according to National Institute of
Health guidelines for animal handling and Colombia Ministry of
Health laws (resolution 8430 of 1993 and law 84 of 1989) and
directly supervised by CORPOAMAZONIA officials [17] and
legal permits and authorization for capture and housing by the
Colombian Ministry of the Environment have been in force for
more than 30 years and there has been strong collaboration with
the Colombian Association of Indian Authorities (ATICOYA,
ASITAM and AZCAITA, representing ,40 Indian communities)
(pertinent documentation available on request), CORPOAMA-
ZONIA 0266 (Dec/2010) being the most recent authorization.
Aotus monkeys were subcutaneously immunised twice or three
times with 250 mg polymerised peptide (on days 1, 20 and 40)
which had been previously homogenised with Freund’s complete
adjuvant for the 1st dose and Freund’s incomplete adjuvant for the
2nd and 3rd doses. Controls received only Freund’s adjuvant and
saline solution on the same days. Blood samples were taken on day
1 before (P0) the first immunisation and 20 days after the 2
nd (II20)
and 3rd (III20) immunisations for immunological analysis [17].
PfEMP1 Detection by Immunofluorescence
Modifications of Staalsoe’s method (Cytrometry 35:329) were
used. Late trophozoite- and schizont-enriched FCB-2 P. falciparum
cultures (5–10% parasitaemia) or highly infected Aotus-adapted P.
falciparum FVO strain-enriched schizonts or late trophozoites were
spun for 5 min at 1,800 rpm and left for a further 20 min to form
sediment, washed three to four times with Tris-buffered Hanks’
solution (TBH) (10 ml 0.15M Tris buffer, pH 7.2, 90 ml 0.9%
NaCl, and 100 ml Hanks’ solution) and then diluted to give 1%
suspension.
Samples were sequentially treated for 15 min with 200 ml of the
appropriate immune serum dilution followed by an anti-goat anti-
Aotus IgG F (ab) 2 fragment conjugated with fluorescein
isothiocyanate. Slides were washed with TBH supplemented with
50 ll Tween 20 per 100 ml between each sequential incubation.
All incubations were performed at room temperature in a
humidified chamber. Monolayers were counterstained by adding
one drop of ethidium bromide per well to enable parasitised
erythrocytes to be visualised. After a few seconds, slides were
washed with distilled water, mounted and read at 100x in oil
immersion.
Western Blot Analysis
FVO strain culture Pf-schizont lysate was electrophoretically
separated and transferred to nitrocellulose membranes. Each
nitrocellulose strip was individually incubated with Aotus monkey
sera diluted 1:200 in blocking solution, washed several times and
incubated with goat anti-Aotus IgG, F(ab) 2 fragment alkaline
phosphatase (AP) conjugated at 1:1,000 dilution and developed
with NBT/BCIP [18].
Challenge and Parasitaemia Assessment
Immunised and control Aotus monkeys were intravenously
infected 20 days after the last immunisation with 100,000 P.
falciparum FVO-strain infected RBC, a dose known to be 100%
infective for these monkeys [17].
Protection was defined as the complete absence of parasites in
blood during the 15 days of the experiment. Non-protected
monkeys developed patent parasitaemia on day 5 or 6, reaching .
5% levels between days 8 and 10. They then received treatment
with antimalarial drugs and were kept in quarantine until ensuring
complete cure, to be returned into the jungle later on [17].
Parasitaemia was measured daily for each monkey, starting on
day 5 after challenge, using immunofluorescence for reading
parasitised RBC percentage on Acridine Orange-stained slides
[17].
CD Analysis
Peptide structures in solution were acquired by circular
dichroism measurement in water and 30% TFE mix. The spectra
were obtained on a JASCO J-810 spectrometer at room
temperature. Data was assessed at 190 to 260 nm wavelength
using 20 nm/min scan rate and 1 nm band with. The data was
collected using Spectra Manager Software and analysed using
SELCOM3, CONTILL and CDSSTR database [19].
(GACxPxRRxxLC) binding motif. Left, schematic representation of PfEMP1 domains showing H-bonds between HABPs (arrows); head structure
recombinant fragments containing NTS and DBL1a (fuchsia), CDR1a (green), DBL3X (orange) and DBL6e (blue), 3D structure determined by X-ray
crystallography. (B) Sequence logos for amino acid conservation in corresponding HABPs according to their frequency in .100 strains; each amino
acid height reflects their relative frequency (%) and thus their contribution to conservation.
doi:10.1371/journal.pone.0088420.g001
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Figure 2. Humoral immune response and protective efficacy induced by PfEMP1 HABPs derived peptides in Aotus monkeys. Aotus
monkeys’ humoral immune responses and protective immunity induced by PfEMP1-derived peptides, according to our serial numbering system with
corresponding amino acid sequence (modifications in bold). Reciprocal IFA antibody titres in bleeding 20 days after second (II20) and third (III20)
immunisation and number of protected monkeys in experimental challenge [12,14].
doi:10.1371/journal.pone.0088420.g002
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NMR Spectroscopy
8 or 10 milligrams of each peptide (6583, 6584 and 6622) were
dissolved in 500 ml TFE-d3/H20 (30/70 v/v). The basic NMR
structure determination protocol [20] was as follows: proton
spectra were assigned by DQF-COSY, TOCSY and NOESY;
TOCSY and DQF-COSY spectra were then used to identify
individual spin systems (amino acids) and NOESY (400 ms mixing
time) was used for determining peptide primary and secondary
structure. TOCSY spectra recorded at different temperatures
(285–315 K) were used to obtain amide temperature coefficients
for predicting hydrogen bonds (-DdHN/DTppb/K), as thoroughly
described beforehand [14,21].
Structural Calculation
Peptide structure was determined by Accelrys software. NOE
peaks, selected from 400 ms NOESY data sets, were integrated
and converted into distance restraints. These restraints were
grouped as strong, medium and weak (1.8–2.5 A˚, 2.5–3.5 A˚, and
3.5–5.0 A˚ distance restraints, respectively). Hydrogen bond
constraints were introduced for slow exchange rate peptide NH,
distance ranges involving likely NH–O hydrogen bonds were set at
1.8–2.5 A˚. A family of 50 structures was obtained using Distance
Geometry (DGII) software and then refined using simulated
annealing protocol (DISCOVER software) to select those having
reasonable geometry and fewer violations.
HAPB Superimposition on Crystallised DBL Protein
Fragments
The 3D structure of DBL domains from PDB 2XU0 [22],
3CML [23] and 2WAU databases [9] was used for selecting
peptide regions presenting high activity binding peptides (HABP)
based on aminoacid sequence alignment between strains. InsightII
biopolymer molecular software (Accelrys Inc.) was used for such
superimposition using backbone superimposition based on RMSD
criteria as well as H-bond measurement between HABPs forming
the niche which is important for binding site receptors.
Results and Discussion
One hundred and fifty 20-mer long peptides were synthesised
using the Dd2var1 clone PfEMP1 amino acid sequence, finding 25
HABPs able to bind specifically to C32 endothelial cells
(amelanotic melanoma-derived) and 10 O+ red blood cell (RBC)
binding HABPs (Figure 1A). Twelve C32 HABPs and two RBC
HABPs were randomly selected for being modified as mHABPs
[12–14].
Ninety-two mHABPs (synthesised using Dd2 sequence, Indo-
china) were used for immunising groups of four to ten Aotus
monkey groups per mHABP, since Aotus immune system is similar
to that of humans (90%–100% identity) [24]. Immunogenicity was
determined by immunofluorescence antibody test (IFA) using the
FCB-2 strain (Colombia) and reactivity by Western blot (WB)
using FVO strain (Vietnam) IE lysate. mHABP protection-
inducing ability was determined following 2nd or 3rd immunisation
by intravenously inoculating 100,000 fresh IE from other Aotus
previously infected with the heterologous Aotus-adapted FVO
strain [12–14].
Figure 3. Immunological assessment in animal model trials
using modified HABPs. (A) IFA assay showing characteristic PfEMP1
dotted pattern on IE membrane, using sera from immunised Aotus
monkeys, corresponding mHABP number on top. (B) WB recognition of
,300 kDa protein in IE lysate from mHABP-immunised Aotus sera. PI:
preimmune sera; NP: non-protected. (C) Comparative course of
parasitaemia in Aotus immunised with mHABPs. Note the complete
absence of parasites (full protective immunity) induced by 24196 (6510)
in the first trial; the second with 10 monkeys gave similar results.
doi:10.1371/journal.pone.0088420.g003
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Around ,30% mHABPs induced high IFA titres (1:160–1:640)
(Figure 2 and 3A), thus demonstrating transcontinental strain-
transcending antibody (Ab) induction, even though most did not
induce any protection against experimental challenge (Figure 2).
Strikingly, mHABP 24196 (GATADYFRLLVTPQNLE) de-
rived from 6510 (GACAPYRRLHVCDQNLEQIE) (mHABP
numbers and their modifications shown hereafter in bold),
containing the GACxPxRRxxLC motif (Figure 1B), induced high
Ab titres ($1:160) in 4/9 Aotus as assessed by IFA (Figure 2); WB
recognised a 310 kDa protein similar to PfEMP1 molecular weight
(Figure 3B). Two Aotus became fully protected against experimen-
tal challenge (0 parasites in blood) throughout the whole
experiment (Figure 3C) and 2/10 from a new group of Aotus
monkeys became totally protected (the same ones displaying high
IFA titres and reacting with the ,310 kDa band (by WB),
demonstrating that 24196 induced strain-transcending fully
protective immunity in 4/19 (,21%) monkeys. 24196 (GATA-
DYFRLLVTPQNLE) displayed a characteristic HLADRb1*0405
binding motif and binding register (highlighted in grey), an allele
found with similar frequency in humans and Aotus (,21%) [24].
6510 did not induce antibodies in animal immunizations
[25,26] and antibodies raised against recombinant proteins
containing this sequence have not recognised 6510, nor African
human immune sera [27], confirming 6510’s immunological
silence [12–14].
Two of the eight Aotus immunised with 37822 (GA-
NIDPFRQMLTLY) derived from 6573
(GACMPPRRQKLCLY), also containing the GACxPxRRxxLC
motif (Figure 1B) (underlined) localised in DBL3X, developed high
Ab titres ($1:160) (Figure 2) and was partially protected,
parasitaemia being maintained at around ,0.1% throughout the
experiment (Figure 3C). 37822 displayed HLADRb1*1501
binding motifs and registers (grey) having similar frequency in
Aotus (,15%) and humans.
Such striking data showed that the canonical GACxPxRRxxLC
motif localised in HB4 (;HBb) [4–6], in the ‘‘head structure’’, is
the critical sequence inducing strain-transcending full protective
immunity when appropriately modified, as in 24196 (6510), whilst
37822 (modified from homologous 6573) localized in DBL3X
induced partial protective immunity. A homologous sequence
(PxRRxxxC) present in DBL4e domain is contained in 6593 (not
used for immunisations) (Figure 1A) and a shorter PxRRxxLx
sequence was found in DBL6e N-terminus in some strains [28],
confirming this motif’s presence in nearly all DBL domains [5].
Interestingly, highly-immunogenic mHABPS, like 9314 (EGQ-
SITQDYPKYQATYGGSP) derived from 6512 (EGQSITQ-
DYPKYQATYGDSP) and 38070 (YNKNKLKIDHRIKIGE)
derived from 6621 (YNKIKHKISHRIKNGEISPC), also induced
high antibody titres and partial protective immunity (parasitaemia
being maintained at ,1.5% in 1/8 monkeys each mHABP
throughout the experiment, Figure 3C), similar to semi-immune
African-adults, suggesting partial strain-transcending immunity,
surpassed by tremendous polymorphism. 9314 and 38070 had
perfectly classical HLADRb1*0101 and HLADRb1*0301 binding
motifs and registers, respectively (grey).
IE usually express only one PfEMP1 at a time but the parasite
switches var gene expression, by a mechanism involving a var
intron re-localization regulated by an 18 bp nuclear binding
element that regulates actin polymerization [29] and leads to the
change in host-cell receptor specificity and serotype [30,31],
evading the immune response [32]. Such polymorphism could
partly explain the partial protective immunity obtained, despite
mHABPs being properly modified [12] and high antibody titres
being induced (Figure 2) but it has been also demonstrated that
Figure 4. Structural characterization of HABPs present in
crystallized Duffy binding like domains (DBL). DBL domain 3D
structure determined by X-ray crystallography A) Head structure: DBL1a
(PDB 2XU0) (pink), C) DBL3X (PDB 3CML) (yellow), F) DBL6e (PDB 2WAU)
(pale blue). 1H-NMR-determined structure localisation, displaying the
perfect fit of HABP 6505 (yellow) superimposed onto DBL1a, 6583 (dark
blue) and 6584 (purple) onto DBL3X and 6622 (grey) onto DBL6e. B, D,
G). H-bonds between HABP residues and their corresponding sequence
on top, displaying relevant residues in binding to A blood group
trisaccharides and CSPG (asterisk and black dot, respectively). E)
Superimposed conserved binding motif fragments from 6510 and
6573. H) CD spectra for corresponding HABPs.
doi:10.1371/journal.pone.0088420.g004
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PfEMP1 specifically induces a large panel of immune suppression
mechanisms among these the early production of human c
interferon [33], but the domain (s) involved in such scape
mechanisms remains to be identified.
Strain-transcending Protection-inducing mHABP 3D
Structure
The 3D structure of the rosette-forming blood group A-binding
Palo Alto VarO strain (Uganda) ‘‘head structure’’ containing the
NTS-DBL1a-CIDR1c region [34], the A4 strain (Brazil) chon-
droitin-sulphate-proteoglycan (CSPG) binding DBL3X domain
[23,35] and the 3D7 strain (unknown origin) DBL6e domain
binding to CSA has been determined by X-ray crystallography
[9].
(reminder: our HABPs are based on Indochina Dd2 sequence).
Our group determined that native HABP 6505 displayed a perfect
a-helix structure by 1H-NMR (Figure 4A, yellow) [14]; when
superimposed onto the NTS-DBL1a 3D structure (Figure 4A,
green) it gave a 0.16 rmsd and 6583 and 6584 (Figure 4B, fuchsia
and dark blue) had a-helix conformation (Figure S1 and Table
S1), giving 0.43 and 0.52 rmsd, respectively, when superimposed
onto the DBL3X sequence [23,35]. It has thus been thoroughly
demonstrated that chemically-synthesised HABPs display the same
3D structure as biologically-derived recombinant proteins [11,12].
Circular dichroism (CD) revealed that 6621 and 6622 had a
helical structure (Figure 4H), while SELCON3 deconvolution
analysis revealed 0.785, 0.836 and 0.898 turn and unordered
structure composition for 6510, 6512 and 6573.
6510 (located in the NTS-DBL1a fragment subdomain S1
between cysteine 3 and 4) contained a short aH1 helix and short
310 H1 helix; partially unordered HABP 6573 (DBL3X sub-
domain S1) only displayed a short a-helix [23], the rest being
unordered.
Thus native 6510 and 6573, parents of strain-transcending
protective immunity inducing 24196 and 37822, respectively,
containing the GACxPxRRxxLC motif, displayed an almost
completely unordered and similar structure in DBL1a and
DBL3X since 6510 superimposition onto 6573 gives 0.65 rmsd
(Figure 4E) explaining in part the cross protective immunity; in
sharp contrast with strain-transcending non-protective antibody-
inducing HABPs having helix structures (6505, 6506, 6583,6584
and 6622) (Figure 4A, C, F) and partially protection inducing 6512
(unordered) and 6621 (a helical and partially unordered, by CD
and X-ray crystallography), suggesting an association between
structure and immunogenicity and protection [12–14].
Modifying H-bond-establishing Residues among cHABPs
Induced Strain-transcending Immunity
3D analysis of 6510 (128GACAPYRRLHVC139DQNLE-
Q*IE*147) showed that C139 HN established an H-bond with
Oe1 from E168 present in 6512 HABP N-terminus (
168EGQ-
SITQDYPKYQATYGDSP187) forming the niche where the A1
blood group terminal a-1,3 linked N-acetylgalactosamine (Gal-
NAc) [34] bound through residues Q145 and E147 (asterisk in
Figure 4B) [34], suggesting that modifying these H-bond-
establishing residues among cHABPs via T139C replacement in
24196 was fundamental [12] for inducing fully-protective, strain-
transcending antibody immunity (Figure 2 and 3C). Antibodies
against these mHABPs might thus have been blocking IE to UE
for rosette formation, thereby impeding IE agglutination and
microvascular obstruction, associated with CM, making 24196
essential for severe malaria control in some individuals, as will be
discussed later on.
By the same token, 6573 (1257HGDTNGA-
CIPPR1268QTQNLCVG1275), containing also conserved binding
motif GACxPxRRxxLC (Figure 1A), established an H-bond
between R1268 HNe and E1456 Oe2 present in 6583
(1455KE1456W1457GEQFCIE1464RLRNYEQNIRE1474); 6583 es-
tablished another H-bond between E1464 Oe1 with OH in
6584 Y1511 (1501CKRKNCEKYKKY1511ISEKKQE1518W1519) to
form a tripartite binding site for CSPG (Figure 4D, dot on top).
Replacing 6573 R1268 by F in 37822 (1262GA-
NIDPF1268RQMLTLY1275) induced strain-transcending immu-
nity, controlling parasitaemia at ,1% throughout the experiment,
due to these cHABPs’ tremendous genetic variability means that
blocking this highly polymorphic CSPG binding site could be
relevant for PAM control and other severe malaria-associated
problems where CSPG is involved.
Two HABPs were localised in DBL6e, consisting of 7 variable
blocks (VB) having limited polymorphism. Completely 310-helix
structure 6622 (2464KKWWDMNKYHIWESML2479) determined
by 1H-NMR (Figure 4F, grey ribbon) is localised in VB4; partially
a-helical 6621 (2446SDKIGKILGDGVGQN2460EKR2463)
(Figure 4F, red ribbon) localised in one of the elbows of DBL6e
domains, in VB4 [28,36], established a H-bond between N2460 O
(6621) and K2464 HN (6622), forming a niche for a non-identified
RBC receptor binding (Figure 4G).
D2456S replacement in 38070 (6621) induced high Ab titres
and partial protective immunity (,1.5% parasitaemia), again
confirming inter-HABP H-bond breaking’s relevance in immune
induction. 38070 displayed binding motifs and registers (grey)
characteristic of HLADRb1*0301 allele (YNKNKLKIDHRI-
KIGE), an allele found ,15% frequency in monkeys and humans.
6622-derived 38074 (MWVDQKRKEWQEIK), inducing non-
protective antibodies, displayed the HLADRb1*0802 binding
motif and register (grey); this HABP is in highly polymorphic
region (Figure 1B).
Recent studies have found predominant transcription of domain
cassette DC8 (UPSB promoter followed by NTSb-DBLa2-
CIDRa1-DBLb12-DBLc4) and DC13 (encoding DBLa1.7-
CIRDa1.4) (both containing the GACxPxRRxxLC motif) in
blood samples from 70% of 88 Tanzanian children suffering
severe malaria. This stresses the importance of 24196 (containing
this motif) in inducing strain-transcending complete protective
immunity against severe malaria in HLADRb1*04 individuals,
suggesting that more HABPs from other IE membrane-expressed
molecules (like histidine-rich protein-II-derived 24230 (6800)
under HLADRb1*07 control [11–14,37], STEVOR [38,39];
RIFIN etc.) are needed to obtain definitive full protection against
severe malaria.
These large functional-structural and immunological studies
show that strain-transcending complete protective immunity
against severe malaria can be fulfilled through previously defined
principles [11–14] modifying the GACxPxRRxxLC conserved
motif (canonical in the PfEMP1 ‘‘head structure’’) binding to
endothelial cells. This, in turn, leads towards a fully-protective,
multi-epitope, multi-stage, minimal subunit-based, chemically-
synthesised definitive antimalarial vaccine [11–14].
Supporting Information
Figure S1 Summary of sequential and medium range NOEs of
6583, 6584 and 6622. Summary of sequential and medium range
NOEs determined in H2O/TFE-d3 (70%/30%). NOE intensity is
indicated by bar height. The numbers inside the diagram are the
3J coupling constants. D represents residues involved in an H-
bond.
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(TIF)
Table S1 Summary of 6583, 6584 and 6622 structure
calculation.
(DOCX)
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